Avitide

Acquired

Avitide is a biotech company in Lebanon, United States, founded in 2013. It has raised $11.0M across 3 rounds, most recently a $7.6M Series C in August 2015.

A new generation of purification technologies for biopharmaceutical manufacturing.

Employees
11–50
Founded
2013
Business Model
B2B
Total Funding
$11.0M
Last Round
$7.6M Series CAug 2015
Rounds
3
Acquired by
Repligen CorporationSep 2021

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 5 investors for this company. The full record is or through the API.

About

Avitide is the industry's premier biopharmaceutical affinity purification partner. The company develops a proprietary portfolio of AVIPure™ affinity ligands and end-to-end purification platforms for novel drug modalities including gene therapies, viral vaccines, bispecific antibodies, and cell-based therapies. Avitide works with partners from concept through commercial resin supply, delivering improved purity, yield, and manufacturing economics—reducing cost of goods and accelerating development timelines for biologic manufacturers. Acquired by Repligen in 2021.

Summary

It lists 11–50 employees. It has raised $11.0M in total across 3 rounds, most recently a $7.6M Series C round in Aug 2015. Investors include Borealis Ventures, NeoMed Management and OrbiMed.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionSep 2021

Sign up to see all 4 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
Isomorphic Labs

AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

London, United Kingdom201–500Artificial Intelligence, Biotech
Series BTotal funding$2.6BMay 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Avitide on Indexed.vc
<a href="https://indexed.vc/companies/avitide"><img src="https://indexed.vc/api/badge/company/avitide" alt="Avitide on Indexed.vc" width="260" height="76" /></a>